

ANCR Symposium 2023

6 - 8 SEPTEMBER, HELSINKI

Programme

PLEASE NOTE THAT THE PROGRAMME IS SUBJECT TO CHANGE!

Wednesday, 6 September

14.00–17.00 Pre-meeting workshops including a coffee break

Workshop 1: Experiences on data sharing and federated analysis
Chairs: Sanna Heikkinen and Karri Seppä, Finnish Cancer Registry

Data from the Nordic cancer registries have been used extensively both in creating the NORDCAN database of cancer statistics and in population-based epidemiological studies. Due to increased requirements for sharing individual data new approaches for conducting analyses based on aggregated data or country-specific estimates have been developed. In the workshop different experiences, challenges, and solutions related to data sharing and federated analyses are discussed. It also includes two presentations:

How is NORDCAN implemented as nordcan.R?

Speaker: Special Adviser Siri Larønningen, Cancer Registry of Norway

Nordic collaborative project on Covid-19 and cancer.

Speaker: Assistant Professor Anna Johansson, Karolinska Institutet, Sweden

After the presentations, the participants in the workshop are divided into groups to discuss the future of Nordic research collaboration.

Workshop 2: Cancer screening – how to weigh benefits and harms
Chairs: Aapeli Nevala and Veli-Matti Partanen, Finnish Cancer Registry

“All screening programmes do harm. Some do good as well and, of these, some do more good than harm at reasonable cost.” (Angela Raffle & John Gray)

A prerequisite for cancer screening programs is that the benefits should outweigh the harms. But how are these benefits and harms quantified? And who decides whether the benefits are greater than harms? Is it the experts or should the general population also have a say in the matter? This workshop also includes two presentations, the evidence of benefits and harms in different cancer screening programs is first reviewed. This is followed by an introduction to ethics and patient-centered decision making in the context of screening. The participants in the workshop are then divided into groups to discuss general and specific cases related to valuation of benefits and harms.

Evidence of benefits and harms in cancer screening

Speaker: Postdoctoral researcher Miriam Elfström, Karolinska Institutet, Sweden

Ethics and patient-centered decision making in cancer screening

Speaker: Doctoral researcher Joel Janhonen, University of Turku, Finland

Workshop 3: Nordic collaboration for expert registrars

Chairs: Gabrielle Gran, Regional Cancer Center South East Sweden and Elina Hermiö, Finnish Cancer Registry

A meeting for coding staff in the Nordic cancer registries with the opportunity to exchange knowledge and news from each registry.

Coding cancer spread; metastasis and TNM

Speaker: Pathologist Ok Målfrid Mangrud, Cancer Registry of Norway

The presentation is followed by a discussion on how do Nordic cancer registries practice coding of metastasis and TNM. After this, there is an open forum: news flash from each registry.

NOTE: As a registered participant you may have already chosen the workshop you will attend (from the workshops 1 and 2 announced earlier). Regardless of your previous choice, it is also possible to attend the third one without notice.

18.00 - 19.00 Reception hosted by the City of Helsinki at Old Town Hall, Aleksanterinkatu 20

19.00 - 21.00 Adventure Tour, Senate Square

Thursday, 7 September

08.30 - 09.30 Registration

09.30 - 09.40 Welcome
Director Janne Pitkäniemi
Finnish Cancer Registry

09.40 - 10.10 Elimination of cervical cancer - Now, later, or never?
Keynote speaker Professor Joakim Dillner
Karolinska Institutet, Sweden

10.10 - 10.30 Coffee break & Poster show

10.30 - 12.00 Session 1: Registration
Chairs: Helgi Birgisson, Icelandic Cancer Registry and Elina Hermiö, Finnish Cancer Registry

Oral presentations

- Completeness and accuracy of multiple myeloma and malignant plasma cell neoplasms in the Finnish Cancer Registry in 2015 – 2019 (*Maarit Leinonen, Finnish Institute for Health and Welfare*)
- Duration of Use of Androgen Deprivation Therapy After Radical Treatment for Prostate Cancer: Nationwide, Population-based Study (*E Lin, Uppsala University, Sweden*)
- Generation and evaluation of model-based synthetic cancer registry data (*Sigrid Leithe, Cancer Registry of Norway*)
- Report on development of a new in-house data platform for data extraction, analysis and export of data. (*Bjarte Aagnes, Cancer Registry of Norway*)
- Accurate pattern-based extraction of complex Gleason score manifestations from pathology reports (*Joonas Miettinen, Finnish Cancer Registry*)

Poster presentations

- Coding of deaths at the Finnish Cancer Registry – differences between the official and FCR cause of death in cancer patients (*Nea Malila, Finnish Cancer Registry*)

12.00 - 13.00 Lunch

13.00 - 14.15 Session 2: Causes and risk factors of cancer
Chairs: Sanna Heikkinen, Finnish Cancer Registry and Lina Steinrud Mørch, Danish Cancer Society

Oral presentations

- NOCCA-new news (*Eero Pukkala, Finnish Cancer Registry*)
- Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden (*Guoqiao Zheng, Danish Cancer Society Research Center*)
- Risk of ovarian cancer after salpingectomy and tubal ligation: prospects on histology and time since the procedure (*Alberte Hjorth Duus, Danish Cancer Society Research Center*)

Poster presentations

- Incidence of second malignant neoplasms among adult cancer patients in Finland (*Hanna Koivisto, Finnish Cancer Registry*)
- Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients (*Laufey Tryggvadottir, Icelandic Cancer Registry*)
- Risk of Secondary Malignancies Among Estonian Childhood Cancer Survivors – a Retrospective Cohort Study (*Keiu Paapsi, National Institute for Health Development, Estonia*)
- Polycystic ovary syndrome and endometrial cancer risk: results from a nationwide cohort study (*Clarissa Frandsen, Danish Cancer Society Research Center*)

14.15 - 15.00 Coffee break & Poster show

15.00 - 16.30 Session 3: Epidemiological and biostatistical methods
Chairs: Mats Lambe, Karolinska Institutet and Karri Seppä, Finnish Cancer Registry

Oral presentations

- Reference adjusted cancer survival measures. What are they and when should they be used? (*Paul Lambert, Karolinska Institutet, Sweden*)
- Loss in life expectancy after a colon cancer diagnosis by socioeconomic group: does the indicator of socioeconomic status matter? (*Elisavet Syriopoulou, Karolinska Institutet, Sweden*)
- Combining cancer registry and screening data – accounting for varying observation schemes for natural progression model of colorectal cancer (*Aapeli Nevala, Finnish Cancer Registry*)
- Parametric Estimation of The Mean Number of Events in The Presence of Competing Risks (*Joshua P. Entrop, Karolinska Institutet, Sweden*)
- Comparing risk of death after radical prostate cancer treatments in an emulated target trial, to demonstrate effectiveness of a new comorbidity index (*Marcus Westerberg, Uppsala University, Sweden*)
- Interactive web applications for presentation of data from Swedish Cancer Quality Registries – development, implementation, and the future (*Pia Löthgren, Regional Cancer Centre South, Sweden*)

17.30 - 19.00 Cruise in the Helsinki archipelago, M/S King

19.00 - Symposium Dinner
Restaurant Saaristo, Klippan Island

Friday, 8 September

09.00 - 09.25 Measuring progress against cancer
Professor Henrik Møller,
The Danish Clinical Registries

09.25 - 10.55 Session 4: Early diagnostics and screening
Chairs: Tytti Sarkeala, Finnish Cancer Registry and Isabelle Soerjomataram, IARC

Oral presentations

- Differences in mammography screening attendance among non-Western immigrants in Denmark, Finland, Iceland and Norway (*Sisse Njor, Randers Regional Hospital, Denmark*)
- Major increase of invasive skin melanoma incidence in Southern Sweden. A prediction model of future incidence and recommendations for prevention and early detection. (*Victor Falini, Regional Cancer Centre South, Sweden*)
- Thirty years of population-based breast cancer screening in Iceland. Quality indicators, pathological predictive factors and interval cancer in women aged 40-69 years (*Álfheiður Haraldsdóttir, Icelandic Cancer Registry*)
- Cervical human papillomavirus screening prevents vaginal and vulvar cancers (*Maija Vahteristo, Finnish Cancer Registry*)
- Cost-Effectiveness of Organized Breast Cancer Screening in Finland (*Filip Siegfriids, Finnish Cancer Registry*)

Poster presentations

- Breast cancer screening participation rates and the effect of the changes made to the program in Estonia during the activity of the Estonian Cancer Screening Register (2015-2021) (*Eliise Leif, National Institute For Health Development, Estonia*)
- Divergent effects of switching from cytology to HPV-based screening in the Nordic countries (*Veli-Matti Partanen, Finnish Cancer Registry*)
- The risk of vaginal, vulvar, and anal precancer and cancer according to high-risk HPV status in cervical cytology samples. (*Sofie Lindquist, Danish Cancer Society Research Center*)
- Effectiveness of cervical testing by age and test history (*Maiju Pankakoski, Finnish Cancer Registry*)

10.55 - 11.15 Coffee break & Poster show

11.15 - 12.40 Session 5: Surveillance and survival from cancer
Chairs: Sirpa Heinävaara, Finnish Cancer Registry and Bjørn Møller, Cancer Registry of Norway

Oral presentations

- Survival of advanced non-small cell lung cancer patients treated with first line immunotherapy compared to previous standard of care and clinical trial results (*Helga Hektoen, Cancer Registry of Norway*)
- Risks of testing positive for SARS-CoV2 and developing severe COVID-19 outcomes among cancer patients in Norway, Denmark and Iceland during 2020 – a population-based study (*Anna Johansson, Karolinska Institutet, Sweden*)
- Improved survival of lung cancer across sex and age in the Nordic countries: The NORDCAN Survival Studies 1990-2016 (*Frida Lundberg, Karolinska Institutet, Sweden*)
- Self-reported fatigue shortly after diagnosis and after one year in a national sample of prostate cancer patients curatively treated or on active surveillance and in a control group (*Ylva Maria Gjelsvik, Cancer*

ANCR Association of the Nordic Cancer Registries

- Difference after curative treatment of stage I-III colorectal cancer. Comparing non-surgery vs. temporal and anatomic patterns. (*Tor Åge Myklebust, Cancer Registry of Norway*)

Supported by  presentations

- Incidence and survival of histologically verified gliomas over 20 years in Norway: Results from a newly established quality registry for brain cancer (*Cassia B. Trewin-Nybråten, Cancer Registry of Norway*)
- One in four Norwegian prostate cancer patients do not want to be involved in shared decision-making, and involvement is associated with lower age, higher education and being married. (*Mona Nilsson, Cancer Registry of Norway*)

12.40 - 13.00 Closure

13.00 - 14.00 Lunch